biossil is an AI-native biopharma company based in Toronto, advancing late-stage programs in life-threatening indications with urgent unmet needs. Its active clinical programs include sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer’s disease.